Christopher Kiff
Bristol, ENG UB81DH, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme.
Journal: Future oncology (London, England)
Published: June 08, 2021
A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: December 10, 2020
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England.
Journal: PharmacoEconomics - open
Published: November 30, 2020
Early Access to Medicines Scheme: real-world data collection.
Journal: Drug discovery today
Published: April 10, 2019
The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology.
Journal: ClinicoEconomics and outcomes research : CEOR
Published: October 18, 2018
Nuedexta for the Treatment of Pseudobulbar Affect: Estimating the Financial Impact to the Scottish NHS.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Showing 1-7 of 7
Last Updated: 09/26/2026